Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amicus Therapeutics (FOLD) Tops Q3 EPS by 8c, Revenues Miss; Raises FY19 Galafold Revenue Guidance
November 11, 2019 7:02 AM ESTAmicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.24), $0.08 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $43.17 million versus the consensus estimate of $47.66 million.
John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. stated, The third quarter represented another consecutive period of significant growth and adoption for Galafold across all geographies, as well as continued momentum in our Pompe pivotal study and our gene therapy pipeline. We are on... More
